Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.
KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.
KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.
The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.
KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).
Product range of the company includes:
Bulk activities
Synthetic
Lavastatin
Simvastatin
I -Ephedrochiloride
l - Ephedrine Sulphate
l - Ephedrine Base (Liquid)
d - Pseudoephedrine Hydrochloride
d - Pseudoephedrine Sulphate
d - Pseudoephedrine Base
dl - Ephedrine Base
n - Methyl Ephedrine
d - Ephedrine Bitartarate
Vitamin C
Vitamin C (Coated)
KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.
KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.
The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.
KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).
Product range of the company includes:
Bulk activities
Synthetic
Lavastatin
Simvastatin
I -Ephedrochiloride
l - Ephedrine Sulphate
l - Ephedrine Base (Liquid)
d - Pseudoephedrine Hydrochloride
d - Pseudoephedrine Sulphate
d - Pseudoephedrine Base
dl - Ephedrine Base
n - Methyl Ephedrine
d - Ephedrine Bitartarate
Vitamin C
Vitamin C (Coated)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.